Valeant CEO Pearson Subpoenaed to Testify at Senate Hearing
- Special Committee on Aging to hold drug price hearing April 27
- Hearing will be committee's third on medication price hikes
Bill Ackman Takes Bigger Role at Valeant
This article is for subscribers only.
Valeant Pharmaceuticals International Inc.’s outgoing chief executive officer, Michael Pearson, was subpoenaed to testify at a hearing next month by a Senate committee investigating drug price hikes.
The April 27 hearing will be the third in a series the Senate Special Committee on Aging has held on pharmaceutical companies that the committee says operate more like hedge funds and have increased the price of decades-old drugs, according to a statement Monday.